

**A COMPARATIVE STUDY OF AN INTEGRATED
PHARMACEUTICAL CARE PLAN AND A ROUTINE CARE IN
BRONCHIAL ASTHMA**

*A Thesis Submitted in Partial Fulfillment of the Requirements for
Master Degree in Pharmaceutical Science (Clinical Pharmacy)*

Submitted By

Rana Rasheed Farrag

BSc in Pharmacy (2008)

Ain Shams University

Under The Supervision of

Prof. Manal EL Hamamsy

Professor of Clinical Pharmacy,

Faculty of Pharmacy,

Ain Shams University

Prof. Mamdouh Zaki

Professor of Clinical Pharmacy,

Faculty of Pharmacy,

Ahram Canadian University

Prof. Taher EL-Naggar

Professor of Chest Diseases,

Faculty of Medicine,

Ain Shams University

Ain Shams University

Faculty of Pharmacy

(Cairo – Egypt)

2014

ABSTRACT

Background:

Bronchial asthma is a chronic chest disease constituting a serious public health problem all over the world. Unfortunately it is still too often poorly controlled and evidence-based guidelines are still insufficiently implemented. A paradigm shift for asthma care implies that the level of asthma control should be continuously monitored and that treatment should be adjusted according to the patients' current asthma-control status. Pharmacists could assist to achieve and maintain asthma control by providing patient education and medical supervision .

Aim: The study compares the effect of asthma care by clinical pharmacist intervention versus routine care on asthma control.

Patients and Methods:

A 2-month randomized, controlled trial was conducted in outpatient clinics of Ain Shams University Hospitals, Cairo, Egypt. Patients were randomly assigned to receive routine care (n=30) or a pre-defined pharmacist intervention (n=30). This intervention mainly focused on patient education, improving inhalation technique and medication assessment. Primary outcome was the level of asthma control, as assessed by the Asthma Control Questionnaire (ACQ) .

Results:

By the end of the study, the intervention patients who received a written action plan significantly improved their ACQ results than routine care group who did not receive a plan ($p < 0.0001$). The intervention also reduced reliever medication use and the frequency of night-time awakenings due to asthma. Inhalation technique and adherence to controller medication were significantly better in the intervention group.

Conclusion:

The present study results provide supportive evidence concerning pharmacists' favorable effects on asthma patient care and support clinical pharmacists as key members of the health care team.

Keywords: Asthma Control Questionnaire; Asthma Action Plan; Patient education; Adherence; Inhalation Technique.

ACKNOWLEDGEMENT

I wish to express my deepest thanks and respect to Prof. Mamdouh Ahmed Zaki, Prof. Taher El-Naggar and Prof. Manal El-Hamamsy for their continuous advice, close supervision and kind support all through this study.

I wish to express my thanks and respect to Dr. Mohsen Fathallah, executive manager of Genuine Research Center, for statistical advice.

I would like to thank Dr. Ahmed Galal, Department of Chest Diseases, Faculty of Medicine, Ain Shams University, as well as all staff members and allied health team for their help complete this study as appropriate.

I wish to express my gratitude to staff members from the Department of Hypersensitivity and Immunology, Faculty of Medicine, Ain Shams University, for their co-operation.

LIST OF CONTENTS

ABSTRACT	i
ACKNOWLEDGEMENT	iii
LIST OF CONTENTS	iv
LIST OF TABLES	vii
LIST OF ILLUSTRATIONS	ix
LIST OF ABBREVIATIONS	xii
INTRODUCTION	1
1. Definition and Pathogenesis	1
2. Factors influencing the development of asthma	15
3. Signs, Symptoms & Diagnosis	25
Reversibility Testing:	35
Differential Diagnosis:	37
4. Management of Asthma	43
Corticosteroids	50
Beta2 – adrenoreceptor Agonists	59
Anticholinergics	65
Leukotriene Modifiers	66
Methylxanthines	69
Immunomodulators	71
Complementary Therapy	73

Bronchial Thermoplasty	75
New Drugs for Asthma.....	76
5. Role of Clinical Pharmacist	79
Asthma Triggers Avoidance.....	79
Proper Inhaler Use.....	80
Choosing the appropriate inhalation device	83
Educating the patient about proper inhaler use	84
Maintaining proper inhaler technique	85
Changing inhalers and patient preferences.....	85
Adherence	86
Written Action Plans and Asthma Self-management	87
Shared Decision Making	87
AIM OF THE WORK	88
PATIENTS & METHODS	89
Patients	89
Methods	90
Setting	90
Study Design	90
Materials	93
Tools of the Study	94
Outcome Measures	111
Statistical Analysis	112

RESULTS	113
Asthma Control:	117
Adherence to Controller Medication	121
Inhalation Technique	122
DISCUSSION	125
Conclusion	134
Study Limitations	134
Recommendations	135
APPENDIX	136
REFERENCES.....	138
الملخص العربي	أ

LIST of TABLES

Table	Page
Table 1.Key inflammatory mediators in the pathogenesis of asthmatic inflammation.	13
Table 2.Asthma Susceptibility Genes Selected Examples	18
Table 3. Clinical features in adults that influence the probability of asthma	26
Table 4. Lung Volumes and Capacities- Explanatory Table.....	34
Table 5. Differential diagnosis for asthma in adults.....	40
Table 6. Asthma Control	44
Table 7. Classification of Asthma Severity in Adults and Adolescents 12 Years and Older	45
Table 8. Assessment of Overall Asthma Control in Adults.....	47
Table 9. Effect of glucocorticoids on transcription of genes related to asthma.....	53
Table 10. Possible adverse effects of oral corticosteroid therapy ...	56
Table 11. Estimated equipotent daily doses of ICS (µg) for adults..	59
Table 12. Different types of inhalation devices available for asthma.....	81
Table 13. Inhaler selection algorithm.	84
Table 14. Pharmaceutical Products Used in the Study	94
Table 15. Asthma Control Questionnaire	96
Table 16. Overview of Patient Education Intervention	103
Table 17. Demographic Characteristics for Patients Participating in the Study.....	114

Table 18. Clinical Characteristics for Patients Participating in the Study at Baseline.	115
Table 19. Clinical Characteristics for Patients at the end of the Study.	116

LIST OF ILLUSTRATIONS

Figure	Page
Figure 1. Cycle of chronic inflammation in patients with asthma.....	5
Figure 2. Pathogenesis of allergic asthmatic inflammation	6
Figure 3. Viral Infections and Asthma Susceptibility	22
Figure 4. Barrel Chest in asthma	30
Figure 5. The mechanics of breathing and the respiratory muscles	31
Figure 6. Atopic skin conditions associated with asthma	32
Figure 7. A schematic illustration of lung volumes and capacities .	34
Figure 8. A spirogram comparing FEV1 values in asthmatic and healthy subjects	35
Figure 9. Reversibility testing	36
Figure 10. Goals of Asthma Management	44
Figure 11. Stepwise management approach for asthma	46
Figure 12. Chronic Inflammation in asthma and potential therapeutic targets	49
Figure 13. Gene regulation by histone acetylation	51
Figure 14. Acetylation of Glucocorticoid Receptor (GR)	52
Figure 15. Cellular and structural effects of glucocorticosteroids	54
Figure 16. Schematic representations of the disposition of inhaled drugs	58
Figure 17. Mechanism of action of β_2 -agonists	61
Figure 18. Actions of β_2 -agonists in airways	61

Figure 19. Complementary actions of LABAs and corticosteroids in the pathophysiology of asthma	62
Figure 20. The molecular interaction between corticosteroids and β 2-agonists	63
Figure 21. Diagram of Leukotriene Formation	66
Figure 22. Omalizumabo (Xolair®) Mechanism of Action	72
Figure 23. Flow of Participants in the Study.....	91
Figure 24. Patient Data Record	92
Figure 25. Flowmate Plus 2500.....	93
Figure 26. Asthma Action Plan (English Version).....	99
Figure 27. Asthma Action Plan (Arabic Version)	100
Figure 28. Pathogenesis of Asthma	104
Figure 29. Patient Education Card-1 Asthma Triggers	105
Figure 30. Patient Education Card-2 Proper Use of MDI (Metered-Dose Inhalers).....	106
Figure 31. Proper Inhaler Technique Checklist for Metered Dose Inhaler (MDI)	107
Figure 32. Proper Inhaler Technique Checklist for Discus Dry Powder Inhaler.....	108
Figure 33. Study Flow Diagram	109
Figure 34. ACQ-scores after a 2-month Follow-up.....	117
Figure 35. dC-FEV1% after a 2-month Follow-up.....	118
Figure 36.ER-Visits and Hospitalization related to asthma	119
Figure 37.Short-Acting β 2-Agonist use after a 2-month follow-up	119

Figure 38. Inhaled Corticosteroid Use after a 2-month follow-up ..	120
Figure 39. Number of Courses of Systemic Steroid Used during a 2-month follow-up	120
Figure 40. % Patients achieved asthma control at the end of the study	121
Figure 41. Patient Adherence to Therapy	122
Figure 42. %Patients Achieved Correct Steps Inhalation Technique at Baseline	123
Figure 43. %Patients Achieved Correct Steps Inhalation Technique at the End of the Study.	124

LIST OF ABBREVIATIONS

5-LO inhibitor	5- Lipooxygenase inhibitor
AC	Adenylyl Cyclase
ACQ	Asthma Control Questionnaire
ACT	Asthma Control Test
ASM	Asthma Self-Management
ATS/ERS	American Thoracic Society/ European Respiratory Society
BA-pMDI	Breath-actuated pressurised Metered-Dose Inhaler
BREATHE	Better Respiratory Education and Asthma Treatment in Hinton and Edson
BT	Bronchial Thermoplasty
CAM	Complementary and Alternative Medicine
c-AMP	cyclic- Adenosine monophosphate
CCL5	Chemokine Ligand 5
CCR3	Chemokine Receptor 3
CD4	Cluster of Differentiation type 4
COPD	Chronic Obstructive Pulmonary Disease
CSS	Churg-Strauss Syndrome
CYP	Cytochrome p450 enzyme
Cys-LTs	Cysteinyl Leukotrienes
DNA	Deoxy Ribonucleic Acid
DPI	Dry Powder Inhaler
ER visits	Emergency Room visits related to asthma
EXCELS study	The Epidemiologic Study of Xolair: Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma (EXCELS)
FC ϵ RI	high-affinity receptor for the Fc region of immunoglobulin E
FDA	Food and Drug Administration
FE _{NO}	Fractional Exhaled Nitric Oxide
FEV1	Forced Expiratory Volume in one second
FVC	Forced Vital Capacity
GINA	Global Initiative for Asthma
GM-CSF	Granulocyte-Macrophage Colony-Stimulating Factor
GR	Glucocorticoid Receptor
GWA	Genome-Wide Association
HDAC2	Histone deacetylase type 2

HLA	Human Leukocyte Antigen
HRV	Human Rhinovirus
IBM Corp.	International Business Machine Corporation
ICS	Inhaled corticosteroid
IgE	Immunoglobulin E
IL-4	Interleukin-4
LABA	Long-acting beta ₂ agonist
LAMA	Long-acting muscarinic antagonist
LRI	Lower Respiratory Infections
LTRA	Leukotriene Receptor Antagonist
m-RNA	messenger- Ribonucleic acid
NCCAM	National Center for Complementary and Alternative Medicine
NNT	Number needed to treat
PC ₂₀	Provocation Concentration of methacholine required to cause a 20% fall in FEV ₁
PCAP	Pharmacy Asthma Care Program
PDE	Phosphodiesterase
PEF	Peak Expiratory Flow
PKA	Protein Kinase A
p-MDI	pressurised Metered-Dose Inhaler
RSV	Respiratory Syncytial Virus
SABA	Short-acting beta ₂ agonist
SFC	Salmeterol/Fluticasone Combination
SPSS	Statistical Package for the Social Sciences
Th2	T-lymphocyte helper cell type 2
TNF- α	Tumor Necrosis Factor-alpha
TSLP	Thymic Stromal Lymphopoietin
VCD	Vocal Cord Dysfunction
VHC	Valved holding chamber
WAAP	Written Asthma Action Plan
WHO	World Health Organization

INTRODUCTION

Asthma is a common chronic disorder with increased prevalence worldwide. World Health Organization (WHO) estimates that 300 million people are affected with asthma (Anandan, et al., 2010).

Asthma is characterized by paroxysmal or persistent symptoms such as dyspnea, chest tightness, wheezing, sputum production and cough, associated with variable airflow limitation and a variable degree of airways hyper-responsiveness to endogenous or exogenous stimuli (Lougheed, et al., 2010). Although good asthma control can be achieved in clinical trials, it is more difficult to achieve in real-life situation studies (Rabe, et al., 2004). Despite advances in asthma management, a large number of patients are still "insufficiently controlled", putting them at risk for asthma-related morbidity and mortality (Mehuys, et al., 2008).

Salama and his colleagues reported that health care delivery was inadequate in Egypt as irrational prescribing and practices were generally widespread and misconceptions were commonly encountered, both among the public and health professionals. Therefore, minimum standards of health care for individuals with asthma must be identified (Salama, et al., 2010).

In an attempt to improve asthma control, the Global Initiative for Asthma (GINA) updated its asthma management guidelines